Annual report pursuant to Section 13 and 15(d)

STOCK OPTIONS AND WARRANTS

v3.22.2
STOCK OPTIONS AND WARRANTS
12 Months Ended
Apr. 30, 2022
Share-Based Payment Arrangement [Abstract]  
STOCK OPTIONS AND WARRANTS

NOTE 6 – STOCK OPTIONS AND WARRANTS

 

2021 Equity Incentive Plan

 

Effective June 30, 2021, the Company implemented the 2021 Equity Incentive Plan (“2021 Equity Plan”) as approved by the Company’s stockholders. The 2021 Equity Plan is administered by the Compensation Committee of the Board and has 166,667 shares available under this plan. The 2021 Equity Plan can issue various types of awards, as follows: stock options, stock appreciation rights, restricted stock, restricted stock units, and cash or other stock-based awards. The 2021 Equity Plan is available to be issued to employees, directors, consultants, and other individuals who provide services to the Company. An incentive stock options (“ISOs”) can only be granted to employees and shall not exceed 10-years (5-years in the case of ISOs granted to any 10% shareholder).

 

Stock Options

 

As of April 30, 2022, the Company had 40,900 outstanding stock options to its directors and officers (collectively, “Employee Options”) and consultants (“Non-Employee Options”).

 

During the years ended April 30, 2022, and 2021, the Company granted 7,334 and 7,333 Employee Options, respectively.

 

The fair value of the Employee Options at the date of grant was estimated using the Black-Scholes-Merton option-pricing model, based on the following weighted average assumptions: 

               
    Years Ended April 30,  
    2022     2021  
Risk-free interest rate     1.1%       0.4%  
Expected volatility     129%       97%  
Expected lives (years)     2.7       2.7  
Expected dividend yield     0.00%       0.00%  

 

The Company’s computation of expected volatility is based on the historical daily volatility of its publicly traded stock. For stock option grants issued during the years ended April 30, 2022, and 2021, the Company used a calculated volatility for each grant. The Company lacks adequate information about the exercise behavior now and has determined the expected term assumption under the simplified method provided for under ASC 718, which averages the contractual term of the Company’s stock options of five years with the average vesting term of two and one-half years for an average of three years. The dividend yield assumption of zero is based upon the fact the Company has never paid cash dividends and presently has no intention of paying cash dividends. The risk-free interest rate used for each grant is equal to the U.S. Treasury rates in effect at the time of the grant for instruments with a similar expected life.

 

During the years ended April 30, 2022, and 2021, the Company granted no Non-Employee Options.

 

A summary of the Company’s stock option activity and related information for the two years ended April 30, 2022 are shown below: 

                 
    Options     Weighted
Average
Exercise Price per Share
    Weighted
Average
Grant Date
Fair Value
per Share
 
                   
Outstanding, April 30, 2020     44,800     $ 94.36     $ 94.155  
Issued     7,333       13.90       13.90  
Forfeited     (10,800 )     94.81       93.90  
Outstanding, April 30, 2021     41,333       79.97       79.97  
Issued     7,334       5.34       5.34  
Forfeited     (7,767 )     148.20       148.20  
Outstanding, April 30, 2022     40,900     $ 53.05     $ 53.05  
Exercisable, April 30, 2022     36,900     $ 58.53     $  
Vested and expected to vest     40,900     $ 53.05     $  

  

A summary of the activity for unvested stock options during the years ended April 30, 2022, and 2021 is as follows: 

           
    Options     Weighted
Average
Grant Date
Fair Value
per Share
 
             
Unvested, April 30, 2020     4,133     $  
Issued     7,334       13.90  
Vested     (7,467 )      
Forfeited            
Unvested, April 30, 2021     4,000        
Issued     7,334       5.34  
Vested     (7,767 )      
Forfeited            
Unvested, April 30, 2022     4,000     $ 2.50  

 

The Company recorded $44,800 and $176,568 of stock-based compensation related to the issuance of Employee Options to certain officers and directors in exchange for services during the years ended April 30, 2022, and 2021, respectively. At April 30, 2022, there remained $7,777 of unrecognized compensation expense related to unvested Employee Options granted to officers and directors, to be recognized as expense over a weighted-average period of the remaining eight months in the calendar year. The unvested options vest at 500 shares per month and are expected to be fully vested on December 31, 2022.

 

The following table summarizes the outstanding stock options by exercise price at April 30, 2022: 

                               
Exercise Price     Number of
Options
Outstanding
    Weighted
Average
Remaining
Contractual Life
(Years) of
Outstanding
Options
    Weighted
Average
Exercisable
Price Per Share
    Number of
Options
Exercisable
    Weighted Average
Exercise Price Per Share
of Exercisable
Options
 
$ 87.00       1,634       0.13     $ 87.00       1,634     $ 87.00  
$ 109.35       1,200       0.19     $ 109.35       1,200     $ 109.35  
$ 133.50       800       0.22     $ 133.50       800     $ 133.50  
$ 82.95       333       0.22     $ 82.95       333     $ 82.95  
$ 83.70       6,000       0.40     $ 83.70       6,000     $ 83.70  
$ 80.10       800       1.35     $ 80.10       800     $ 80.10  
$ 80.85       667       0.50     $ 80.85       667     $ 80.85  
$ 102.45       333       0.58     $ 102.45       333     $ 102.45  
$ 97.35       333       0.72     $ 97.35       333     $ 97.35  
$ 74.25       6,000       1.13     $ 74.25       6,000     $ 74.25  
$ 57.00       800       2.40     $ 57.00       800     $ 57.00  
$ 60.60       667       1.00     $ 60.60       667     $ 60.60  
$ 55.50       333       1.09     $ 55.50       333     $ 55.50  
$ 51.00       333       1.22     $ 51.00       333     $ 51.00  
$ 61.20       6,000       1.61     $ 61.20       6,000     $ 61.20  
$ 36.00       667       1.50     $ 36.00       667     $ 36.00  
$ 37.05       333       1.59     $ 37.05       333     $ 37.05  
$ 15.75       333       1.72     $ 15.70       333     $ 15.70  
$ 10.05       6,000       2.20     $ 10.05       6,000     $ 10.05  
$ 26.55       667       2.00     $ 26.55       667     $ 26.55  
$ 16.20       333       2.09     $ 16.20       333     $ 16.20  
$ 3.19       334       2.22     $ 3.19       334     $ 3.19  
$ 2.50       6,000       2.81     $ 2.50       2,000     $ 2.50  
  Total       40,900       1.21     $ 53.05       36,900     $ 58.53  

 

The aggregate intrinsic value of outstanding options as of April 30, 2022, was $0. This represents options whose exercise price was less than the closing fair market value of the Company’s common stock on April 30, 2022, of approximately $2.33 per share.

 

Warrants

 

The warrants issued by the Company are equity classified. The fair value of the warrants was recorded as additional paid-in-capital, and no further adjustments are made.

 

The Company concluded the following warrants met the permanent equity criteria classification as they are freestanding financial instruments that are legally detachable and separately exercisable from the shares of common stock with which they were issued. The warrants are immediately exercisable and do not embody an obligation for the Company to repurchase the shares. The warrants also permit the holders to receive a fixed number of shares upon exercise and do not provide any guarantee of value or return.

 

The Company elected to early adopt ASU No. 2020-06 Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40) as of May 1, 2021. The early adoption of ASU No.2020-06 had an immaterial effect on the Company’s consolidated financial statements.

 

Effective August 12, 2021, the Company issued Common Stock Warrant Agreements (“Common Warrants”) with respect to the First Offering. The Company issued Common Warrants to purchase 4,028,528 shares of common stock based upon the underwriting agreement with H.C. Wainwright & Co., LLC (“Wainwright”). The Common Warrants have a term of five years with an exercise price of $4.25 per warrant share, are fully vested upon issuance and have a cashless exercise feature. Using the Black-Scholes-Merton option pricing model, the Company determined the aggregate fair value of these Common Warrants to be approximately $9,385,000 and comprises the non-cash equity issuance costs as presented on the Consolidated Statements of Cash Flows of $34,477,000.

 

Additionally, with respect to the First Offering, the Company issued common stock warrant agreements to Wainwright (“Underwriter Warrants”) to purchase 264,706 shares of common stock. The Underwriter Warrants have a term of five years with an exercise price of $5.3125 per warrant share, are fully vested upon issuance and have a cashless exercise feature. Using the Black-Scholes-Merton option pricing model, the Company determined the aggregate fair value of these Underwriter Warrants to be approximately $601,000 and comprises the non-cash equity issuance costs as presented on the Consolidated Statements of Cash Flows of $34,477,000.

 

Effective August 12, 2021, the Company issued 899,027 pre-funded warrants (“Pre-funded Warrants”) to purchase common stock and Common Warrants based upon the underwriting agreement with Wainwright with respect to the First Offering. The Pre-funded Warrants required a payment upon issuance of $4.249 per warrant share and are fully vested upon issuance. The Company received approximately $3,820,000 from the issuance of the Pre-funded Warrants. The Pre-funded Warrants have an exercise price of $0.001 per share, are exercisable immediately, have a cashless exercise feature and do not have an expiration date. In August 2021, all 899,027 of the Pre-funded Warrants issued under the underwriting agreement were exercised. The Company received $899 as a result of the exercise of the Pre-funded Warrants and issued 899,027 shares of common stock as a result of the exercise notices. There was no additional effect on the Pre-funded Warrants as they were fully exercised.

 

Effective August 23, 2021, the Company issued additional Common Stock Warrant Agreements (“Series A Warrants”) with respect to its Registered Direct Public offering. The Company issued Series A Warrants to purchase 7,000,000 shares of common stock based upon the Securities Purchase Agreement with certain institutional investors. The Series A Warrants have a term of five years with an exercise price of $5.00 per warrant share, are fully vested upon issuance, have a cashless exercise feature and are exercisable immediately. Using the Black-Scholes-Merton option pricing model, the Company determined the aggregate fair value of these Series A Warrants to be approximately $21,340,000 and comprises the non-cash equity issuance costs as presented on the Consolidated Statements of Cash Flows of $34,477,000.

 

Effective August 23, 2021, the Company issued additional Common Stock Warrant Agreements (“Placement Agent Warrants”) with respect to its Registered Direct Public Offering. The Company issued Placement Agent Warrants to purchase 1,050,000 shares of common stock to Wainwright or its designees based upon Wainwright acting as placement agent. The Placement Agent Warrants have a term of five years with an exercise price of $6.25 per warrant share, are fully vested upon issuance, have a cashless exercise feature and are exercisable immediately. Using the Black-Scholes-Merton option pricing model, the Company determined the aggregate fair value of these Placement Agent Warrants to be approximately $3,151,000 and comprises the non-cash equity issuance costs as presented on the Consolidated Statements of Cash Flows of $34,477,000.

 

Effective August 23, 2021, the Company issued Pre-funded Warrants pursuant to the Registered Direct Offering to purchase 5,570,000 shares of common stock in the amount of approximately $27,844,000 which required payments upon issuance of $4.999 per warrant share. The Pre-funded Warrants have an exercise price of $0.001 per share, are fully vested upon issuance, are immediately exercisable, have a cashless exercise feature and do not have an expiration date. As of April 30, 2022, 4,620,000 of the Pre-funded Warrants have been exercised for aggregate gross proceeds of $4,620, which resulted in the issuance of 4,620,000 shares. As of April 30, 2022, the remaining unexercised Pre-funded Warrants were 950,000 shares that can be exercised for $950. The Company received $4,749,050 pursuant to the issuance of the Pre-funded Warrants and these shares remain unissued as of April 30, 2022, (see Note 13 – Subsequent Events).

 

In August 2021, the Company received twenty-seven cash exercise notices relating to the Common Warrants with respect to the First Offering totaling 2,522,387 warrant shares. The Company received approximately $10,720,000 and issued 2,522,387 shares of common stock as a result of the exercise notices.

 

Series A Warrants and Placement Agent Warrants were issued pursuant to the Securities Purchase Agreement dated as of August 19, 2021. At the time, the Series A Warrants and the Placement Agent Warrants were issued, neither the Series A Warrants, the Placement Agent Warrants nor the underlying common stock was registered pursuant to the Securities Act. The Company registered the common stock underlying the Series A Warrants and the Placement Agent Warrants pursuant to a Registration Statement on Form S-3 (“Registration Statement”) filed with the Commission on November 8, 2021. The Registration Statement became effective on November 17, 2021.

 

A summary of the Company’s warrant activity and related information for the two years ended April 30, 2022, are shown below: 

           
    Warrants    

Weighted
Average
Exercise Price

Per Share

 
Outstanding, April 30, 2020     31,927     $ 75  
Issued     22,911        
Exercised     (40,524 )      
Expired     (11,333 )      
Outstanding, April 30, 2021     2,981       58.70  
Issued     18,812,261        
Exercised     (8,041,414 )      
Expired     (1,093 )      
Outstanding, April 30, 2022     10,772,735        
Exercisable, April 30, 2022     10,772,735     $ 4.59  

  

The following table summarizes additional information concerning warrants outstanding and exercisable at April 30, 2022: 

                 
Exercise Prices   Number of
Warrant Shares
Exercisable at
April 30, 2022
    Weighted
Average
Remaining
Contractual
Life Years
    Weighted
Average
Exercise Price Per Share
 
                   
$37.50     1,333       0.24          
$45.00     555       0.06          
$4.25     1,506,141       4.28          
$5.3125     264,706       4.28          
$5.00     7,000,000       4.32          
$6.25     1,050,000       4.31          
$0.001     950,000                
      10,772,735       4.31     $ 4.59